Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study

Hepatology Research

Volumn 40, Issue 4, 2010, Pages 376-382

  Imai, Kenji ^a   Takai, Koji ^a   Nishigaki, Yoichi ^b   Shimizu, Shogo ^c   Naiki, Takafumi ^a   Hayashi, Hideki ^b   Uematsu, Takahiro ^c   Sugihara, Junichi ^c   Tomita, Eiichi ^b   Shimizu, Masahito ^a   Nagaki, Masahito ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Gifu Municipal Hospital   (Japan)

^c GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Homeostatic Model Assessment of Insulin Resistance; Insulin resistance; Radiofrequency ablation; Recurrence

Indexed keywords

SERUM ALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION;

EID: 77954360465     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00616.x     Document Type: Article

References (39)

1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008, 14:4300-8.
2. Koike Y, Shiratori Y, Sato S. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000, 32:1216-23.
3. Ikeda K, Saitoh S, Tsubota A. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993, 71:19-25.
4. Adachi E, Maeda T, Matsumata T. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995, 108:768-75.
5. Nagashima I, Hamada C, Naruse K. Surgical resection for small hepatocellular carcinoma. Surgery 1996, 119:40-5.
6. Ishii H, Okada S, Nose H. Predictive factors for recurrence after percutaneous ethanol injection for solitary hepatocellular carcinoma. Hepatogastroenterology 1996, 43:938-43.
7. Wideroff L, Gridley G, Mellemkjaer L. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89:1360-5.
8. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-8.
9. Kingston ME, Ali MA, Atiyeh M, Donnelly RJ. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology 1984, 87:688-94.
10. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994, 21:1135-9.
11. Mehta SH, Brancati FL, Strathdee SA. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-6.
12. Marchesini G, Brizi M, Morselli-Labate AM. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-5.
13. Shintani Y, Fujie H, Miyoshi H. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-8.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-19.
15. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002, 19:527-34.
16. Digestive system tumors, liver. TMN Classification of Malignant Tumours 1997, 74-7. Sobin LHWittekind CH. International Union Against Cancer (UICC), eds., 5th, edn., New York, Wiley-Liss
17. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005, 54:1914-25.
18. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004, 159:1160-7.
19. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001, 10:937-41.
20. Silverman DT, Schiffman M, Everhart J. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999, 80:1830-7.
21. Lindblad P, Chow WH, Chan J. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999, 42:107-12.
22. Rose DW, Saltiel AR, Majumdar M, Decker SJ, Olefsky JM. Insulin receptor substrate 1 is required for insulin-mediated mitogenic signal transduction. Proc Natl Acad Sci USA 1994, 91:797-801.
23. Skolnik EY, Batzer A, Li N. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993, 260:1953-5.
24. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001, 21:57-69.
25. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-33.
26. Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cells 1991, 3:1-7.
27. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996, 32A:30-8.
28. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005, 22(2):3-10. Suppl
29. Scott KA, Arnott CH, Robinson SC. TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene 2004, 23:6954-66.
30. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-5.
31. Yu J, Qiao L, Zimmermann L. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006, 43:134-43.
32. Marchesini G, Bianchi G, Merli M. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003, 124:1792-801.
33. Muto Y, Sato S, Watanabe A. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-13.
34. Nishitani S, Takehana K, Fujitani S, Sonaka I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1292-300.
35. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 2008, 22:105-12.
36. Urata Y, Okita K, Korenaga K, Uchida K, Yamasaki T, Sakaida I. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. Hepatol Res 2007, 37:510-16.
37. Muto Y, Sato S, Watanabe A. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006, 35:204-14.
38. Yoshiji H, Noguchi R, Kitade M. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009, 44:483-91.
39. Shimizu M, Shirakami Y, Iwasa J. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res 2009, 15:3068-75.